Table 1 Characteristics of included patients.
From: Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era
Adjuvant dataset | Neoadjuvant dataset | |||||
|---|---|---|---|---|---|---|
Number of patients assessed for KELIM in previous studies | 2868 | 1582 | ||||
Number of patients assessable for long complete remission > 5 years | 2029 (70.7%) | 1452 (91.8%) | ||||
Long complete remission > 5 years | Yes | No | Total | Yes | No | Total |
N (%) | N (%) | N | N (%) | N (%) | N | |
Pathological subtypes | ||||||
Serous | 57 (3.6.%%) | 1517 (96.4%) | 1574 | 24 (2.2%) | 1047 (97.8) | 1071 |
Other subtypes | 25 (5.5%) | 427 (94.4%) | 452 | 12 (3.2%) | 369 (96.8%) | 381 |
Disease stage | ||||||
Stage I–II | 48 (25.9%) | 137 (74.1%) | 185 | 2 (Stage II only) (22.2%) | 7 (Stage II only) (77.8%) | 9 (Stage II only) |
Stage III | 32 (2.1%) | 1448 (97.9%) | 1480 | 26 (3.1%) | 811 (96.9%) | 837 |
Stage IV | 2 (0.5%) | 362 (99.5%) | 364 | 8 (1.3%) | 598 (98.7%) | 606 |
Surgery outcomes | ||||||
Complete surgery with no residual lesions | NA | NA | NA | 29 (5.7%) | 476 (94.3%) | 505 |
Incomplete surgery with residual lesions | NA | NA | NA | 4 (0.6%) | 602 (99.4%) | 606 |
Standardised KELIM | Median 1.14 [1.02–1.20] | Median 0.81 [0.78–0.83] | /// | Median 1.54 (1.34–1.79] | Median 1.04 [1.01–1.08] | /// |
Favourable ≥1.0 days−1 | 51 (7.9%) | 590 (92.1%) | 641 | 29 (3.6%) | 767 (96.4%) | 796 |
Unfavourable <1.0 days−1 | 31 (2.2%) | 1357 (97.8%) | 1388 | 7 (1.0%) | 649 (99.0%) | 656 |
Total | 82 (4.0%) | 1947 (96.0%) | 2029 | 36 (2.4%) | 1416 (97.6%) | 1452 |
BRCA mutational status | ||||||
BRCA1 mutation | NA | NA | NA | 2 (3.1%) | 62 (96.9%) | 64 |
BRCA2 mutation | NA | NA | NA | 5 (16.7%) | 25 (83.3%) | 30 |
BRCA wild-type | NA | NA | NA | 7 (1.9%) | 348 (98.1%) | 355 |
Missing | NA | NA | NA | 22 (2.1%) | 981 (97.9%) | 1003 |
